Calithera Biosciences Inc. (CALA) Hits New 12-Month Low at $2.87
Calithera Biosciences Inc. (NASDAQ:CALA) shares reached a new 52-week low during trading on Tuesday . The company traded as low as $2.87 and last traded at $2.96, with a volume of 303,618 shares changing hands. The stock had previously closed at $3.15.
A number of research analysts recently commented on CALA shares. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Zacks Investment Research downgraded shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $10.38.
The stock has a 50-day moving average of $3.67 and a 200 day moving average of $4.95. The firm’s market cap is $56.87 million.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.05. On average, analysts anticipate that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current fiscal year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.